$EVFM
Evofem Biosciences, Inc.

2016 Q2 Form 10-Q Financial Statement

#000156459016023997 Filed on August 11, 2016

View on sec.gov

Income Statement

Concept 2016 Q2 2015 Q2
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $980.0K $1.730M
YoY Change -43.35% 64.76%
% of Gross Profit
Research & Development $1.428M $7.470M
YoY Change -80.88% 703.22%
% of Gross Profit
Depreciation & Amortization $20.00K $20.00K
YoY Change 0.0% 100.0%
% of Gross Profit
Operating Expenses $2.520M $9.199M
YoY Change -72.61% 364.61%
Operating Profit -$2.520M -$9.199M
YoY Change -72.61%
Interest Expense -$250.0K -$280.0K
YoY Change -10.71% -6.67%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$2.660M -$9.480M
YoY Change -71.94% 315.79%
Income Tax
% Of Pretax Income
Net Earnings -$2.657M -$9.480M
YoY Change -71.97% 315.79%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$1.142M -$4.158M
COMMON SHARES
Basic Shares Outstanding 13.67M
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q2 2015 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $21.50M $63.00M
YoY Change -65.87% 447.83%
Cash & Equivalents $21.47M $62.95M
Short-Term Investments
Other Short-Term Assets $800.0K $800.0K
YoY Change 0.0% 60.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $22.20M $63.80M
YoY Change -65.2% 431.67%
LONG-TERM ASSETS
Property, Plant & Equipment $200.0K $200.0K
YoY Change 0.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $200.0K $200.0K
YoY Change 0.0%
Total Long-Term Assets $400.0K $400.0K
YoY Change 0.0% 300.0%
TOTAL ASSETS
Total Short-Term Assets $22.20M $63.80M
Total Long-Term Assets $400.0K $400.0K
Total Assets $22.60M $64.20M
YoY Change -64.8% 430.58%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.100M $3.000M
YoY Change -63.33% 650.0%
Accrued Expenses $1.500M $1.800M
YoY Change -16.67% 80.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $1.190M $1.200M
YoY Change -0.8%
Total Short-Term Liabilities $3.732M $6.000M
YoY Change -37.8% 328.57%
LONG-TERM LIABILITIES
Long-Term Debt $2.810M $8.600M
YoY Change -67.33% 120.51%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $2.810M $8.600M
YoY Change -67.33% 56.36%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.732M $6.000M
Total Long-Term Liabilities $2.810M $8.600M
Total Liabilities $6.542M $14.60M
YoY Change -55.19% 111.59%
SHAREHOLDERS EQUITY
Retained Earnings -$121.5M
YoY Change
Common Stock $137.6M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $16.04M $49.60M
YoY Change
Total Liabilities & Shareholders Equity $22.58M $64.20M
YoY Change -64.83% 430.58%

Cashflow Statement

Concept 2016 Q2 2015 Q2
OPERATING ACTIVITIES
Net Income -$2.657M -$9.480M
YoY Change -71.97% 315.79%
Depreciation, Depletion And Amortization $20.00K $20.00K
YoY Change 0.0% 100.0%
Cash From Operating Activities -$2.630M -$7.810M
YoY Change -66.33% 306.77%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change
Cash From Investing Activities $0.00 $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 20.00K 40.00K
YoY Change -50.0% -98.98%
NET CHANGE
Cash From Operating Activities -2.630M -7.810M
Cash From Investing Activities 0.000 0.000
Cash From Financing Activities 20.00K 40.00K
Net Change In Cash -2.610M -7.770M
YoY Change -66.41% -490.45%
FREE CASH FLOW
Cash From Operating Activities -$2.630M -$7.810M
Capital Expenditures $0.00 $0.00
Free Cash Flow -$2.630M -$7.810M
YoY Change -66.33% 306.77%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
285077
us-gaap Operating Income Loss
OperatingIncomeLoss
-15837204
us-gaap Investment Income Interest
InvestmentIncomeInterest
14317
us-gaap Interest Expense Debt
InterestExpenseDebt
419181
us-gaap Interest Expense Debt
InterestExpenseDebt
556923
us-gaap Net Income Loss
NetIncomeLoss
-16379810
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.20
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
13673961
us-gaap Depreciation And Amortization
DepreciationAndAmortization
22875
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-6139
us-gaap Paid In Kind Interest
PaidInKindInterest
104424
us-gaap Share Based Compensation
ShareBasedCompensation
676028
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-110253
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2852802
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-426128
us-gaap Early Repayment Of Senior Debt
EarlyRepaymentOfSeniorDebt
5514058
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
485942
us-gaap Payments Of Loan Costs
PaymentsOfLoanCosts
52400
CY2015Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
200000
CY2016Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2015Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1729287
CY2015Q4 neot Accrued Clinical Trial Expenses Current
AccruedClinicalTrialExpensesCurrent
1422810
CY2015Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
903148
CY2015Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7469928
CY2016Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
961782
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
13750016
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-112831757
CY2016Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
22580428
CY2016Q2 us-gaap Liabilities Current
LiabilitiesCurrent
3732272
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
1374
CY2016Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
13815589
CY2016Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2016Q2 us-gaap Stockholders Equity
StockholdersEquity
16038555
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
23807295
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
40111972
CY2015Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2015Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2015Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2015Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
13750016
CY2016Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-121515802
CY2016Q2 neot Accrued Clinical Trial Expenses Current
AccruedClinicalTrialExpensesCurrent
489940
CY2016Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
1190431
CY2016Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2015Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
2756351
CY2016Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
9099501
CY2016Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2016Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
2809601
CY2015Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2016Q2 us-gaap Common Stock Value
CommonStockValue
1381
CY2016Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
137552976
CY2016Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2016Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2015Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
136637678
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2016Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
13815589
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3612513
us-gaap Operating Income Loss
OperatingIncomeLoss
-8301007
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4688494
us-gaap Investment Income Interest
InvestmentIncomeInterest
36143
us-gaap Operating Expenses
OperatingExpenses
15837204
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3666608
us-gaap Operating Expenses
OperatingExpenses
8301007
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12170596
CY2015Q2 us-gaap Operating Expenses
OperatingExpenses
9199215
CY2015Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-9199215
CY2015Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
6862
CY2015Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
7205176
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
18525
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-6033875
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
75947516
us-gaap Interest Paid
InterestPaid
366567
CY2016Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
279547
CY2015Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
279547
CY2016Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
128599
CY2015Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
93175
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1363027
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
563856
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.28
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
2.26
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
65573
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
488449
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1372861
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.09
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.09
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.69
CY2016Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
172676
CY2015Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
376942
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
887363
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
676028
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
1787328
CY2016Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
3667621
neot Lease Expiration Period
LeaseExpirationPeriod
2020-03
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
19092
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
40856
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-16276800
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-12992561
CY2015Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
62954955
us-gaap Interest Paid
InterestPaid
377500
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p></div>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentrations of Credit Risk</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash due to the financial position of the depository institution in which those deposits are held.</p></div>
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1444118
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1598391
CY2016Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
71257
neot Noncancelable Operating Lease Agreement Date
NoncancelableOperatingLeaseAgreementDate
2015-01-20
CY2016Q2 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
191262
CY2016Q2 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
395520
CY2016Q2 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
410850
CY2016Q2 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
431508
CY2016Q2 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
109293
CY2016Q2 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
1538433

Files In Submission

Name View Source Status
0001564590-16-023997-index-headers.html Edgar Link pending
0001564590-16-023997-index.html Edgar Link pending
0001564590-16-023997.txt Edgar Link pending
0001564590-16-023997-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
neot-10q_20160630.htm Edgar Link pending
neot-20160630.xml Edgar Link completed
neot-20160630.xsd Edgar Link pending
neot-20160630_cal.xml Edgar Link unprocessable
neot-20160630_def.xml Edgar Link unprocessable
neot-20160630_lab.xml Edgar Link unprocessable
neot-20160630_pre.xml Edgar Link unprocessable
neot-ex101_48.htm Edgar Link pending
neot-ex311_8.htm Edgar Link pending
neot-ex321_9.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending